Dendritic Cancer Cell Therapy: 2018 Pipeline Insights - Detailed Analysis of 25+ Products with More Than 15 Companies Involved -

DUBLIN--()--The "Dendritic Cancer Cell Therapy- Pipeline Insights, 2018" report has been added to's offering.

This report outlays comprehensive insights of present scenario and growth prospects across Dendritic Cancer Cell Therapy.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 25+ products with more than 15+ companies involved. Some of the emerging products include DCVax-L of Northwest Biotherapeutics, CreaVax of Creagene, and Rocapuldencel-T of Argos Therapeutics.

Products covered by Phase

  • Phase III, Phase II, Phase I
  • IND
  • Pre-clinical & Discovery
  • Inactive (Dormant & Discontinued)

Overview of pipeline development activities for Dendritic Cancer Cell Therapy

  • Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
  • Therapeutic segmentation of products for Dendritic Cancer Cell Therapy.
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.


  • Provides an overview of therapeutic pipeline activity for Dendritic Cancer Cell Therapy across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Dendritic Cancer Cell Therapy therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Dendritic Cancer Cell Therapy

Companies Featured

  • Argos Therapeutics
  • Asterias Pharmaceuticals
  • Bellicum Pharmaceuticals
  • CiMaas
  • Creagene
  • DCPrime
  • Diavacs
  • Enonchian
  • Immunicum
  • ImmunoCellular Therapeutics
  • Kiromic Biopharma
  • Medigene
  • MedImmune
  • MicroVAX
  • Northwest Biotherapeutics
  • Orbis
  • Sotio
  • Tella
  • Vaxil Bio Therapeutics

Key Topics Covered

  1. Executive Summary
  2. Overview
  3. Introduction
  4. Mechanism of Action
  5. Types of Cancer Treated
  6. Dendritic Cancer Cells vs Other Therapies
  7. Side effects of Dendritic Cancer Cell Therapy
  8. Limitations of Dendritic Cancer Cell Therapy
  9. Conclusion and Future Perspectives
  10. Pipeline Therapeutics (Active Products)
  11. Pipeline Therapeutics (Inactive Products)
  12. Comparative Analysis
  13. Late Stage Products (Phase III)
  14. Comparative Analysis
  15. CreaVax: Creagene
  16. Product Description
  17. Research and Development
  18. Product Development Activities
  19. The list continues.
  20. Mid Stage Products (Phase II)
  21. Comparative Analysis
  22. BSK-01: Kiromic Biopharma
  23. Product Description
  24. Research and Development
  25. Product Development Activities
  26. The list continues..
  27. Early Stage Products (Phase I & IND)
  28. Comparative Analysis
  29. Pre-clinical and Discovery Stage Products
  30. Comparative Analysis
  31. Therapeutic Assessment: Active Products
  32. Assessment by Stage and Product Type
  33. Assessment by Route of Administration
  34. Assessment by Stage and Route of Administration
  35. Assessment by Molecule Type
  36. Assessment by Stage and Molecule Type
  37. Inactive Products
  38. Comparative Analysis

For more information about this report visit

Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics, Oncology Drugs

Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics, Oncology Drugs